To Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild AD Dementia
Public ClinicalTrials.gov record NCT04311515. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2A Study to Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild Alzheimer's Disease (AD) Dementia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The study is designed as a classic, randomized, double blind, placebo controlled, parallel group study including one active dose of PU AD and matching placebo, designed to assess safety, tolerability and pharmacological effects of oral PU AD (dihydrochloride salt) in subjects with mild AD
Study identification
- NCT ID
- NCT04311515
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 4 participants
Conditions and interventions
Conditions
Interventions
- Tau Positron emission tomography (PET) Radiation
- Fluorodeoxyglucose (FDG) Positron emission tomography (PET) Radiation
- Cerebrospinal fluid (CSF) Biomarkers Diagnostic Test
- Blood Biomarkers Diagnostic Test
- Rating Scales Behavioral
- PU-AD Drug
- Placebo Drug
Radiation · Diagnostic Test · Behavioral + 1 more
Eligibility (public fields only)
- Age range
- 55 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2020 (Actual)
- Primary completion
- Sep 9, 2020 (Actual)
- Completion
- Nov 15, 2022 (Actual)
- Last update posted
- Nov 17, 2022
2020 – 2022
United States locations
- U.S. sites
- 10
- U.S. states
- 2
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| SFM Clinical Research, LLC | Boca Raton | Florida | 33487 | — |
| Brain Matters Research | Delray Beach | Florida | 33445 | — |
| JEM Research | Lake Worth | Florida | 33462 | — |
| Med-Care Research | Miami | Florida | 33165 | — |
| Miami Dade Medical Research Institute, LLC | Miami | Florida | 33173 | — |
| Neurostudies, Inc | Port Charlotte | Florida | 33952 | — |
| Premiere Research Institute | West Palm Beach | Florida | 33407 | — |
| Conquest Research LLC | Winter Park | Florida | 32789 | — |
| Advanced Clinical Institute, Inc. | Neptune City | New Jersey | 07753 | — |
| Princeton Medical Institute | Princeton | New Jersey | 08540 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04311515, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 17, 2022 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04311515 live on ClinicalTrials.gov.